From: Genomic signatures characterize leukocyte infiltration in myositis muscles
Subject ID | Age | Gender | Disease type* | Muscle | Disease duration (months) | Treatments |
---|---|---|---|---|---|---|
GEIM12 | 74 | F | DM | Biceps | 1 | None |
GEIM54 | 62 | M | PM | Quadriceps | 24 | None |
GEIM57 | 38 | F | Normal | Biceps | N/A | N/A |
GEIM63 | 37 | F | Normal | Biceps | N/A | N/A |
GEIM64 | 77 | M | NM | Biceps | 6 | Pred |
GEIM90 | 90 | M | PM | Deltoid | 3 | None |
GEIM96 | 86 | F | PM | Biceps | 3 | None |
GEIM127 | 68 | F | IBM | Biceps | 36 | Azathioprine |
GEIM133 | 60 | F | Normal | Quadriceps | N/A | N/A |
GEIM174 | 36 | F | PM | Biceps | 3 | None |
GEIM272 | 25 | F | DM (with PFA) | Biceps | 3 | Pred x 4 days |
GEIM306 | 64 | F | NM | Biceps | 17 | Pred |
GEIM312 | 76 | F | PM | Biceps | 96 | None |
GEIM315 | 39 | F | DM | Biceps | 3 | None |
GEIM322 | 58 | F | PM | Biceps | 180 | None |
GEIM331 | 87 | F | PM | Deltoid | 36 | Pred |
GEIM335 | 71 | F | IBM | Quadriceps | 24 | None |
GEIM340 | 83 | F | NM | Biceps | 66 | Pred |
GEIM349 | 28 | F | DM | Biceps | 18 | Pred, Azathioprine |
GEIM354 | 76 | M | IBM | Biceps | 60 | None |
GEIM363 | 79 | F | IBM | Biceps | 36 | None |
GEIM365 | 41 | M | Normal | Biceps | N/A | N/A |
GEIM368 | 61 | F | Normal | Quadriceps | N/A | N/A |
GEIM372 | 61 | M | IBM | Quadriceps | 84 | Dexamethasone taper |
GEIM373 | 80 | F | IBM | Quadriceps | 90 | None |
GEIM374 | 47 | F | IBM | Quadriceps | 54 | None |
GEIM375 | 50 | F | NM | Quadriceps | 6 | None |
GEIM376 | 37 | M | DM | Deltoid | 4 | None |
GEIM377 | 50 | M | IBM | Biceps | 24 | None |
GEIM380 | 61 | M | IBM | Quadriceps | 24 | None |
GEIM382 | 30 | F | DM (with PFA) | Deltoid | 1 | None |
GEIM383 | 44 | F | DM (with PFA) | Deltoid | 2 | Pred x 1 month |
GEIM385 | 61 | F | PM | Biceps | 60 | Etancercept |
GEIM389 | 40 | M | DM (with PFA) | Biceps | 5 | N/A |
GEIM391 | 71 | M | NM | Quadriceps | 7 | None |
GEIM397 | 77 | M | IBM | Biceps | 84 | None |